Entropy Technologies LP Takes $2.16 Million Position in Stryker Corporation $SYK

Entropy Technologies LP acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, Holdings Channel.com reports. The fund acquired 5,467 shares of the medical technology company’s stock, valued at approximately $2,163,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Stryker in the second quarter worth about $26,000. Sachetta LLC lifted its stake in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares in the last quarter. Ridgewood Investments LLC boosted its holdings in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares during the period. Ransom Advisory Ltd purchased a new position in shares of Stryker during the 1st quarter valued at $37,000. Finally, MTM Investment Management LLC bought a new position in shares of Stryker in the second quarter worth $38,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 522,618 shares of company stock valued at $185,577,237. 5.90% of the stock is owned by insiders.

Stryker Trading Up 2.2%

SYK stock opened at $368.35 on Friday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a market capitalization of $140.87 billion, a PE ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company’s 50 day moving average price is $369.38 and its two-hundred day moving average price is $380.68. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SYK shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research note on Wednesday. Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Barclays boosted their price objective on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Redburn Partners set a $420.00 target price on shares of Stryker in a research note on Thursday, September 18th. Finally, BTIG Research reissued a “buy” rating and issued a $410.00 price target on shares of Stryker in a research note on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.